Colin Garner
Nessuna posizione attualmente
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Susan Proctor | F | - |
Xceleron Ltd.
Xceleron Ltd. Miscellaneous Commercial ServicesCommercial Services Xceleron Ltd. provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It was founded in 1997 and is located in York, the United Kingdom. | 7 anni |
Ian Mark Buckley-Golder | M | 72 |
Xceleron Ltd.
Xceleron Ltd. Miscellaneous Commercial ServicesCommercial Services Xceleron Ltd. provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It was founded in 1997 and is located in York, the United Kingdom. | - |
John W. Holaday | M | 78 |
Xceleron Ltd.
Xceleron Ltd. Miscellaneous Commercial ServicesCommercial Services Xceleron Ltd. provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It was founded in 1997 and is located in York, the United Kingdom. | - |
Frank Armstrong | M | 67 |
Xceleron Ltd.
Xceleron Ltd. Miscellaneous Commercial ServicesCommercial Services Xceleron Ltd. provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It was founded in 1997 and is located in York, the United Kingdom. | - |
Edward William Anthony Lascelles | M | 49 |
Xceleron Ltd.
Xceleron Ltd. Miscellaneous Commercial ServicesCommercial Services Xceleron Ltd. provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It was founded in 1997 and is located in York, the United Kingdom. | - |
Michael John Butler | M | 64 |
Xceleron Ltd.
Xceleron Ltd. Miscellaneous Commercial ServicesCommercial Services Xceleron Ltd. provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It was founded in 1997 and is located in York, the United Kingdom. | 5 anni |
Iyad Omari | M | - |
Xceleron Ltd.
Xceleron Ltd. Miscellaneous Commercial ServicesCommercial Services Xceleron Ltd. provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It was founded in 1997 and is located in York, the United Kingdom. | - |
Bernard Chan | M | - |
Xceleron Ltd.
Xceleron Ltd. Miscellaneous Commercial ServicesCommercial Services Xceleron Ltd. provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It was founded in 1997 and is located in York, the United Kingdom. | - |
June Garner | F | - |
Xceleron Ltd.
Xceleron Ltd. Miscellaneous Commercial ServicesCommercial Services Xceleron Ltd. provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It was founded in 1997 and is located in York, the United Kingdom. | 16 anni |
Jeremy Hague | M | - |
Xceleron Ltd.
Xceleron Ltd. Miscellaneous Commercial ServicesCommercial Services Xceleron Ltd. provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It was founded in 1997 and is located in York, the United Kingdom. | 10 anni |
J. Scott Tarrant | M | - |
Xceleron Ltd.
Xceleron Ltd. Miscellaneous Commercial ServicesCommercial Services Xceleron Ltd. provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It was founded in 1997 and is located in York, the United Kingdom. | - |
Graham Lappin | M | - |
Xceleron Ltd.
Xceleron Ltd. Miscellaneous Commercial ServicesCommercial Services Xceleron Ltd. provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It was founded in 1997 and is located in York, the United Kingdom. | 12 anni |
Mark Seymour | M | - |
Xceleron Ltd.
Xceleron Ltd. Miscellaneous Commercial ServicesCommercial Services Xceleron Ltd. provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It was founded in 1997 and is located in York, the United Kingdom. | 6 anni |
June McLenaghan | F | - |
Xceleron Ltd.
Xceleron Ltd. Miscellaneous Commercial ServicesCommercial Services Xceleron Ltd. provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It was founded in 1997 and is located in York, the United Kingdom. | 10 anni |
Ian Bedford | M | - |
Xceleron Ltd.
Xceleron Ltd. Miscellaneous Commercial ServicesCommercial Services Xceleron Ltd. provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It was founded in 1997 and is located in York, the United Kingdom. | 5 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Regno Unito | 15 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Colin Garner
- Contatti personali